We are live on !
Find out more
Stonepine Capital Management Portfolio holdings
AUM
$159M
Turnover
51.35%
1-Year Est. Return
62.27%
This Fund
S&P 500
This Quarter Est. Return
+6.92%
1 Year Est. Return
+62.27%
3 Year Est. Return
+321.39%
5 Year Est. Return
+335.25%
10 Year Est. Return
+1,440.6%
AUM
$97.5M
AUM Growth
+$12.7M
(+15%)
Cap. Flow
-$2.23M
Cap. Flow % of AUM
Cap. Flow %
-2.29%
Top 10 Holdings %
Top 10 Hldgs %
80.62%
Holding
30
New
10
Increased
6
Reduced
5
Closed
7
Avg Time Held
0.2
years
Top 10 Avg Time Held
0.3
years
Top 20 Avg Time Held
0.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
QLT Inc
QLTI
|
+$5.81M |
| 2 |
ALR
Alere Inc
ALR
|
+$3.25M |
| 3 |
Pacira BioSciences
PCRX
|
+$2.56M |
| 4 |
Vericel
VCEL
|
+$2.4M |
| 5 |
SCMP
Sucampo Pharmaceuticals
SCMP
|
+$2.34M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SCLN
Sciclone Pharmaceuticals
SCLN
|
+$12.7M |
| 2 |
Vanda Pharmaceuticals
VNDA
|
+$12.2M |
| 3 |
PTX
Pernix Therapeutics Holdings
PTX
|
+$3.38M |
| 4 |
CTIC
CTI BioPharma
CTIC
|
+$1.99M |
| 5 |
ZLTQ
Zeltiq Aesthetics
ZLTQ
|
+$1.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 70.89% |
| 2 | Miscellaneous | 29.11% |
Similar funds
TC
Stonepine Capital Management's Q2 2016 Portfolio in Review
As of Q2 2016, Stonepine Capital Management held 30 positions worth $97.5M, up 15% from $84.8M the previous quarter. Its ten largest holdings account for 81% of the portfolio.
Stonepine Capital Management's Q2 2016 filing shows 10 new, 6 increased, 5 reduced and 7 closed positions. Its largest new stake was QLT Inc: 3,779,274 shares worth $5.37M. The largest sale was Sciclone Pharmaceuticals, an estimated $12.7M.
By sector, the portfolio is most concentrated in Healthcare at 71% of assets, down from 92% a quarter earlier, followed by Miscellaneous.
- Stonepine Capital Management's largest Q2 2016 buy was QLT Inc: 3,779,274 shares worth $5.37M.
- Stonepine Capital Management added most to Vericel in Q2 2016, an estimated $2.4M increase.
- Stonepine Capital Management's biggest Q2 2016 reduction was Sciclone Pharmaceuticals, cutting an estimated $12.7M.
- Stonepine Capital Management fully exited Pernix Therapeutics Holdings in Q2 2016, selling an estimated $3.38M.
- Stonepine Capital Management's ten largest holdings make up 81% of its $97.5M portfolio in Q2 2016.
- Stonepine Capital Management opened 10 new positions and closed 7 in Q2 2016.
- Stonepine Capital Management's portfolio value rose 15% quarter-over-quarter to $97.5M.
Based on Stonepine Capital Management's 13F filing for Q2 2016, filed 10 Aug 2016.